¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"endolymphatic shunt operation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • portosystemic shunt
    ¹®¸ÆÀü½Å¼ÇÆ®
  • peritoneovenous shunt
    º¹°­Á¤¸Æ¼ÇÆ®
  • right to left shunt
    ¿À¸¥¿ÞÂÊ¼ÇÆ®, ¿ìÁÂ¼ÇÆ®
  • splenorenal shunt
    Áö¶óÄáÆÏÁ¤¸Æ¼ÇÆ®, ºñÁ¤¸Æ½ÅÁ¤¸Æ¼ÇÆ®
  • subduro-peritoneal shunt
    ³ú°æ¸·ÇϺ¹°­¼ÇÆ®
  • shunt
    1. Áö¸§±æ, »çÀÕ±æ 2. ¼ÇÆ®, Áö¸§
  • shunt circuit
    ¼ÇƮȸ·Î
  • shunt effect
    Áö¸§±æÈ¿°ú, ¼ÇƮȿ°ú
  • shunt malfunction
    Áö¸§±æ±â´ÉºÒ·®, ¼ÇÆ®±â´ÉºÒ·®
  • ventriculoatrial shunt
    ³ú½Ç½É¹æ¼ÇÆ®
  • ventriculoperitoneal shunt
    ³ú½Çº¹°­¼ÇÆ®
  • Ammon¡¯s operation
    ¾Æ¸ó¼ö¼ú, ´«¹°ÁÖ¸Ó´ÏÀý°³(¼ú)
  • cleisis operation
    Æó¼â¼ö¼ú
  • compensating operation
    º¸»ó¼ö¼ú
  • concrete operation
    ±¸Ã¼ÀûÁ¶ÀÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • recession operation
    µÚ¿Å±è¼ú, ÈÄÀü¼ú
  • second-look operation
    ÀÌÂ÷È®Àμö¼ú, ÀÌÂ÷Ã߽üö¼ú
  • shortening operation
    ´ÜÃà¼ú
  • sling operation
    °É±â¼ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • portosystemic shunt
    ¹®¸ÆÀü½Å¼øÈ¯Áö¸§¼ú, ¹®¸ÆÀü½Å¼øÈ¯¿¬°á¼ú
  • renal shunt
    ÄáÆÏÇ÷·ùÁö¸§±æ, ½ÅÀåÇ÷·ùÁö¸§±æ
  • shunt
    Áö¸§±æ, Áö¸§¼ú, ´Ü¶ô
  • splenorenal shunt
    Áö¶óÄáÆÏÁ¤¸ÆÁö¸§¼ú, ºñ½ÅÁ¤¸Æ¿¬°á¼ú
  • subarachnoid ureteral shunt
    °Å¹Ì¸·¹Ø¿ä°üÁö¸§±æ, °Å¹Ì¸·¹Ø¿ä°üÁö¸§¼ú
  • subduro-atrial shunt
    ³ú°æ¸·¹Ø½É¹æÁö¸§¼ú
  • subduro-peritoneal shunt
    ³ú°æ¸·¹Ø¹è¾ÈÁö¸§¼ú
  • ventriculoatrial shunt
    ³ú½Ç½É¹æÁö¸§¼ú
  • ventriculocaval shunt
    ³ú½Ç»ó´ëÁ¤¸ÆÁö¸§¼ú
  • ventriculosubarachnoid shunt
    ³ú½Ç°Å¹Ì¸·¹ØÁö¸§¼ú
  • Caldwell-Luc operation
    À§Åα¼±ÙÄ¡¼ö¼ú, »ó¾Çµ¿±ÙÄ¡¼ú
  • cleisis operation
    Æó¼â¼ö¼ú
  • compensating operation
    ´ë»ó¼ö¼ú
  • concrete operation
    ±¸Ã¼ÀûÁ¶ÀÛ
  • covering operation
    ÇǺ¹¼ö¼ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Gonins operation
    °í³Ã¾¾¼ö¼ú
  • Halsteds method (operation)
    Ȧ½ºÅ×µå ¼ö¼ú.
  • Hegar s method =H s operation
    Çì°¡¼ö ¼ú.
  • Hummelsheims operation
    Çϸá»þÀÓ¼ö¼ú
  • Jensens operation
    Á¨½¼¼ö¼ú
  • Kronleins operation
    Å©·Û¶óÀμö¼ú
  • Millard operation
    ¹Ð¶óµå¼ö¼ú¹ý ¾ðìÀ̼ö ¼ú .
  • Millard operation
    ¹Ð¶óµå¼ö¼ú¹ý, ¾ðìÀ̼ö¼ú
  • Scheie operation-thermal sclerostomy
    ½¦ÀÌ¿¡¼ö¼ú
  • ablative operation
    ÀýÁ¦(¼ö)¼ú(ï·ð¶âú), Àý´Ü(¼ö)¼ú(ï·Ó¨âú).
  • high forceps operation
    °íÀ§°âÀںи¸¼ú.
  • plastic operation
    ¼ºÇü¼ö¼ú(à÷û¡â¢âú).
  • plication operation
    ÁÖ¸§¼ºÇü¼ú.
  • radical conservative operation
    °í½ÄÀû ±ÙÄ¡¼ö¼ú(°í½ÄÀû±ÙÄ¡¼ö¼ú).
  • radical operation
    ±ÙÄ¡¼ö¼ú(±ÙÄ¡¼ö¼ú).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hydrops, endolymphatic
    ³»¸²ÇÁ¼öÁ¾
  • space, endolymphatic
    ³»¸²ÇÁ°­, ¼Ó¸²ÇÁ°ø°£{ÇØ}
  • space, endolymphatic duct
    ³»¸²ÇÁ°­, ¼Ó¸²ÇÁ°ø°£{ÇØ}
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®, µ¿Á¤¸Æ´Ü¶ô(¡­Ó­Õ©)
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®, µ¿Á¤¸Æ´Ü¶ô(¡­´Ü¶ô).
  • bypass shunt
    ¿ìȸ·Î ´Ü¶ô(éæüÞÖØÓ­Õ©).
  • bypass shunt
    ȸ·Î°£µµ, ȸ·Î´Ü¶ô(ȸ·Î´Ü¶ô), ¿ìȸ·Î´Ü¶ô.
  • bypass shunt
    ¼øÈ­ [½Å¿Ü,ÈäºÎ]ȸ ·Î°£µµ, ȸ·Î´Ü¶ô(üßÖØÓ­Õ©), ¿ìȸ·Î´Ü¶ô.
  • cardiac shunt
    ½É´Ü¶ô(ãýÓ­Õ©)
  • hexose monophosphate shunt
    ÀÏÀλêÇí¼Ò½º¼ÇÆ®<--´Ü¶ô>
  • intracardiac shunt
    ½ÉÀå³»´Ü¶ô(¡­Ó­Õ©).
  • juxtamedullary shunt
    (¼öÁú)±ÙÁ¢ºÎ´Ü¶ô(âÐòõÐÎïÈݻӭթ).
  • left-to-right shunt
    Á¿ì¼ÇÆ®(ñ§éÓ¡­)
  • portacaval shunt
    ¹®¸Æ´ëÁ¤¸Æ¹®ÇÕ(¼ú)(¹®¸Æ´ëÁ¤¸Æ¹®ÇÕ¼ú).
  • porto-systemic shunt
    ¹®¸ÆÃ¼´Ü¶ô(Ó­Õ©)<--¼ÇÆ®>
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • stage operation
    ´Ü°èÀû¼ö¼ú
  • stereotaxic operation
    Á¤À§³ú¼ö¼ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
VU shunt Ventriculo-Ureteral shunt
SP sacroposterior; sacrum to pubis; salivary progesterone; schizotypal personality; semi-private [room]...
Op, op. Operation; ¼ö¼ú
VSD Ventricular Septal Defect
  ? Types of VSD
    1. Subpulmonic(=...
BI background interval; bacterial or bactericidal index; base-in [prism]; basilar impression; Billroth ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
OECD Organisation for Economic Co-operation and Development
SLO Second look operation
SHAM Sham operation
SH sham operation
SO sham operation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Burow's operation
    ºÎ·Î ¼ö¼ú
  • Caldwell-Luc operation
    ÄݵåÀ£-·è-¼ö¼ú
    »ó¾Ç ¼Ò±¸Ä¡ »ó¹æ °ßÄ¡ ¿Í¿¡ Àý°³¸¦ °¡ÇÏ¿© »ó¾Çµ¿¿¡ ±¸¸ÛÀ» ¸¸µé°í »ó¾Çµ¿ ¿°À» Ä¡·áÇÏ´Â ¼ú½Ä.
  • diez operation
    µðÁî ¼ö¼ú
    ¿äºÎ±³°¨ ½Å°æÀý ÀýÁ¦¼ú.
  • Egger operation
    Eggers ¼ö¼ú
  • emergency operation
    ÀÀ±Þ ¼ö¼ú
  • emergent operation
    ÀÀ±Þ ¼ö¼ú
  • endoscopic operation
    ³»½Ã°æÇÏ ¼ö¼ú
  • flap operation
    ÇÇºÎÆÇ ¼ºÇü¼ú
  • Fontan operation
    Æùź ¼ö¼ú¹ý
    Æùź ¼ö¼ú¹ýÀº »ï÷ ÆÇ¸· Æó¼âÁõ ȯÀÚ¿¡¼­ ¿ì½É½ÇÀ» »ç¿ëÇÒ ¼ö ¾øÀ» °æ¿ì¿¡ ¿ì½É¹æ°ú Æóµ¿¸ÆÀ» Á÷Á¢ ¿¬°áÇϴµ¥¼­ ½ÃÀ۵Ǿú´Ù. ÀÌ·¯ÇÑ ¼ö¼úÀº ÁÂÃø ½É½Ç°ú ´Þ¸® ¿ìÃø ½É½ÇÀº Æóµ¿¸Æ Ç÷·ù¸¦ À¯ÁöÇϴµ¥ ²À ÇÊ¿äÇÏÁö´Â ¾Ê´Ù´Â ¹ß°ß¿¡¼­ ½ÃÀÛµÈ °ÍÀε¥ ¿ì½É½Ç ¹ßÀ° ºÎÀü ȯÀÚ, »ï÷ ÆÇ¸· Æó¼âÁõ ȯÀÚ, ½É½ÇÀÌ Çϳª ¹Û¿¡ ¾ø´Â ´Ü½É½Ç ȯÀÚ µî¿¡¼­ »ç¿ëµÇ°í ÀÖ´Ù. ¹°·Ð °³½É¼ú ÇÏ¿¡ ½Ç½ÃÇϸç ÃÖ±Ù¿¡´Â ¼ö¼ú¹ýÀÌ ¸¹ÀÌ º¯ÇüµÇ¾î ´ëÁ¤¸Æ¿¡¼­ Á÷Á¢ ¶Ç´Â µµ°ü
  • interval operation
    Áß°£±â ¼ö¼ú, °£Çæ±â ¼ö¼ú
  • Jaboulay's operation
    ÀÚºÒ·¹ ¼ö¼ú
    °ñ¹ÝÀÇ ¿Ü¹ÝÃøÀ» ÇÔ²² ÀýÁ¦ÇÏ´Â ´ëÅð Àý´Ü¼ú.
  • Lane's operation
    ·¹ÀÎ ¼ö¼ú
    ¼ÒÀåÀÇ ¸ÍÀåºÎ¸¦ Àý´ÜÇÏ¿© Á÷Àå ¶Ç´Â S»ó °áÀå°ú ºÀÇÕÇϰí, °áÀåÀÇ ´ëºÎºÐÀ» Á¦°ÅÇÏ´Â ¼ö¼ú.
  • Lanz's operation
    ¶õÃ÷ ¼ö¼ú
    »óÇǺ´ÀÇ ¿Ü°úÀûÀÎ ¿ä¹ýÀ¸·Î¼­, ±¤±Ù¸· ÇÑ Á¶°¢À» Àß¶ó³»¾î ´ëÅð°ñ¿¡ »ðÀÔÇÏ´Â ¼ö¼ú.
  • lateral repositioned flap operation
    Ä¡Àº Ãø¹æ À̵¿¼ú
  • major operation
    ´ë ¼ö¼ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
pentose monophosphate shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
reversed shunt Right-to-left shunt that had previously been a left-to-right shunt; rarely the opposite.
(05 Mar 2000)
mesocaval shunt Anastomosis of the side of the superior mesenteric vein to the proximal end of the divided inferior vena cava, for control of portal hypertension, h-shunt anastomosis of the inferior vena cava to the superior mesenteric vein, using a synthetic conduit or autologous vein.
(05 Mar 2000)
peritoneovenous shunt An operation for the continuous emptying of ascitic fluid into the venous system. Fluid removal is based on intraperitoneal and intrathoracic superior vena cava pressure differentials and is performed via a pressure-sensitive one-way valve connected to a tube traversing the subcutaneous tissue of the chest wall to the neck where it enters the internal jugular vein and terminates in the superior vena cava. It is used in the treatment of intractable ascites.
(12 Dec 1998)
right-to-left shunt The passage of blood from the right side of the heart into the left (as through a septal defect), or from the pulmonary artery into the aorta (as through a patent ductus arteriosus); such a shunt can occur only when the pressure on the right side exceeds that in the left, as in advanced pulmonic stenosis, or when the pulmonary artery pressure exceeds aortic pressure, as in one form of Eisenmenger's syndrome or in tricuspid atresia.
(05 Mar 2000)
Warburg-Dickens-Horecker shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
Warburg-Lipmann-Dickens-Horecker shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
Warren shunt Anastomosis of the splenic end of the divided splenic vein to the left renal vein.
Synonym: distal splenorenal shunt.
(05 Mar 2000)
Waterston shunt Creation of a narrow (about 3 mm) opening between the ascending aorta and the subjacent right pulmonary artery to increase pulmonary circulation in cyanotic heart disease with decreased pulmonary flow.
(05 Mar 2000)
complications of ventriculo-peritoneal shunt <radiology> Kinking, interruption, exit from peritoneal cavity with growth, through processus vaginalis to scrotum, CSFoma, mass effect exhibited on bowel gas pattern with malfunctioning shunt, lack of movement of shunt tip with positional or temporal change, perforation of hollow viscus (e.g., bowel or bladder)
(12 Dec 1998)
portacaval shunt Surgical anastomosis between portal and systemic veins, surgical anastomosis between the portal vein and the vena cava, as in an Eck fistula.
(05 Mar 2000)
portacaval shunt, surgical Surgical portasystemic shunt between the portal vein and inferior vena cava.
(12 Dec 1998)
portasystemic shunt A shunt between any parts of the portal and systemic venous systems, including portacaval, mesocaval, splenorenal shunt's or spontaneously occurring shunt's.
(05 Mar 2000)
portasystemic shunt, surgical Surgical venous shunt between the portal and systemic circulation to effect decompression of the portal circulation. It is performed primarily in the treatment of bleeding oesophageal varices resulting from portal hypertension. Types of shunt include portacaval, splenorenal, mesocaval, splenocaval, left gastric-caval (coronary-caval), portarenal, umbilicorenal, and umbilicocaval.
(12 Dec 1998)
portasystemic shunt, transjugular intrahepatic A type of surgical portasystemic shunt to reduce portal hypertension with associated complications of oesophageal varices and ascites. It is performed percutaneously through the jugular vein and involves the creation of an intrahepatic shunt between the hepatic vein and portal vein. The channel is maintained by a metallic stent. The procedure can be performed in patients who have failed sclerotherapy and is an additional option to the surgical techniques of portocaval, mesocaval, and splenorenal shunts. It takes one to three hours to perform. (jama 1995;273(23):1824-30)
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á